Heart failure patients with concomitant iron failure
Conditions
Interventions
Comprehensive iron therapy group: iron therapy with sodium ferrous citrate/daprodustat for iron deficiency.
Conservative treatment group: only observation of iron kinetics and no treatment for iron de
Sponsors
Toyota Toshiaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) hospitalized for heart failure 2) Iron deficiency (ferritin 13 g/dL and 12 g/dL and <15 g/dL 4) 18 years of age or older 5) Written consent has been obtained from the patient
Exclusion criteria
Exclusion criteria: 1) Active bleeding disorders 2) Hematopoietic tumor 3) Transfusion within 90 days prior to enrollment 4) Planned non-pharmacologic treatment for heart failure 5) Catecholamine-dependent status (via intravenous administration) 6) Pregnant women, women who wish to become pregnant during participation in the study, and breastfeeding mothers 7) Inappropriate to participate in this study by the attending physician or principal/participating investigator (e.g., life expectancy of less than 1 year)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Short Physical Performance Battery (SPPB) total score at 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| -Change in SBBP total score, 6-minute walk distance, peak VO2, and NYHA -Change in hemoglobin level and NT-proBNP -Change in Left ventricular ejection fraction and Global Longitudinal Strain on transthoracic echocardiogram -All-cause mortality (cardiac death, sudden cardiac death, cardiovascular death, non-cardiac death, death at discharge) -Readmissions for heart failure (excluding laboratory admissions) and cardiac-related death (cardiac death, sudden cardiac death, cardiovascular death) -Cerebrovascular events (myocardial infarction, acute coronary syndrome, stroke [cerebral infarction, cerebral hemorrhage]) and cardiac death (cardiac death, sudden cardiac death, cardiovascular death) -Readmissions for heart failure (excluding laboratory admissions) -Non-pharmacologic treatment of unplanned heart failure -Implementation of standard treatment for heart failure (outpatient cardiac rehabilitation, optimal drug therapy) -Hemorrhagic complications (GUSTO classification, BARC classification) -Anemia -Malignant tumor -Dialysis -Adverse events | — |
Contacts
Public ContactToshiaki Toyota
Kobe City Medical Center General Hospital
Outcome results
None listed